In this article, we will discuss Durvalumab (Warnings-24). So, let’s get started.
Grade 3 immune-mediated type 1 diabetes mellitus occurred in <0.1% (1/1889) of patients receiving Durvalumab. This patient required long-term insulin therapy and Durvalumab was permanently discontinued. Two additional patients (0.1%, 2/1889) had events of hyperglycemia requiring insulin therapy that did not resolve at the time of reporting.